A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients

Journal of Nephrology

Volumn 17, Issue 5, 2004, Pages 687-692

  Mahajan, Sandip ^b   Boulton, Helen ^a   Gokal, Ram ^a,c  

^a Manchester Institute of Nephrology and Transplantation   (United Kingdom)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Anemia; Darbepoetin alfa; Peritoneal dialysis

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UREA; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FREQUENCY ANALYSIS; HEMOGLOBIN DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INTRACUTANEOUS TEST; KIDNEY DISEASE; MALE; OPEN STUDY; PERITONEAL DIALYSIS; REFERENCE VALUE; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS;

EID: 16644392147     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979; 93: 449-58.
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
3. Eschbach JW, Abdulhadi MH, Browne JK. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.
4. National Kidney Foundation: DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis 1997; 30 (suppl 3): S192-240.
5. Working Party for European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure: European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (suppl 5): S1-50.
6. Egrie JC, Browne JK. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 (suppl 1): S3-10.
7. Macdougall IC, Gray SJ, Elston O. Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5.
8. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375-81.
9. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ. Randomized, controlled trial of Darbepoetin Alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-8.
10. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-175.
11. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51; 76-89: 1992.
12. Vanrenterghem Y, Jadoul M, Foret M. Novel erythropoiesis stimulating protein (NESP) administered once every 3 weeks by the intravenous or subcutaneous route maintains hemoglobin (Hb) in dialysis patients. ASN/ISN World Congress of Nephrology. J Am Soc Nephrol 2001: 365A.